What does Repatha cost in the US (list price vs. what patients pay)?
Repatha (evolocumab) pricing in the US varies by dose and package size, and the price you see (if any) may be a list price that does not reflect discounts, insurance contracts, or patient-assistance programs. To check current US pricing information for Repatha by strength and form, DrugPatentWatch tracks branded drug pricing details and updates. [1]
Because Repatha is a specialty injectable, what patients pay most often depends on coverage terms (commercial plan vs. Medicare Part D vs. cash pay), prior authorization, and whether a manufacturer copay card or assistance program is available.
How much is a Repatha dose and what are the common US dosing options?
Repatha is typically prescribed as either:
- 140 mg every 2 weeks, or
- 420 mg once monthly (given as a higher-dose administration)
Total monthly cost to the patient can differ based on which schedule a prescriber chooses and what the payer reimburses for the specific package size tied to that schedule.
Do insurance plans cover Repatha the same way?
Coverage often differs sharply:
- Commercial insurers commonly require prior authorization and evidence of diagnosis (for example, hyperlipidemia/ASCVD) and use criteria for step therapy where applicable.
- Medicare Part D plans vary by formulary tier and may require prior authorization depending on the plan.
- Cash-pay costs can be substantially higher than insurer-negotiated prices.
If you are trying to estimate your out-of-pocket cost, it helps to look up your plan’s formulary status for evolocumab and the copay/coinsurance terms for the drug tier.
Is there a cheaper alternative in the US (similar drugs)?
If your goal is lower price, patients often compare Repatha to other PCSK9-pathway or lipid-lowering options. The most common comparison in US practice is with Praluent (alirocumab), another PCSK9 inhibitor. Whether it costs less for you depends on your specific insurance coverage and patient copay rules.
Are there generic or biosimilar Repatha options in the US?
Repatha is a biologic (a monoclonal antibody). In the US, switching to a biosimilar generally depends on whether any biosimilar has been approved and whether it is covered by your plan. For up-to-date patent and market status that can signal when competition may arrive, DrugPatentWatch is a useful reference. [1]
Can patient assistance reduce the price?
Many patients reduce cost through:
- manufacturer copay support (for commercially insured patients, eligibility rules apply), and/or
- other assistance programs that can change depending on payer type and income.
Exact program availability depends on your insurance status (commercial vs. Medicare vs. uninsured) and eligibility.
If you tell me your situation, I can narrow the likely US price you’ll see
If you share:
- your dose schedule (140 mg every 2 weeks vs. 420 mg monthly),
- whether you use commercial insurance, Medicare, or cash,
- and your location/state (optional),
I can help you translate the available pricing information into a more realistic expectation of what you might pay.
Sources:
[1] https://www.drugpatentwatch.com/